
Hyloris' Annual General Shareholders Meeting on June 9, 2026

Liège, Belgium – 8 May 2026 – 07:30 AM CET – Regulated Information - Hyloris Pharmaceuticals SA (“Hyloris”) (Euronext Brussels: HYL), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announces that its Annual General Shareholders Meeting will be held on Tuesday, 9 June 2026, at 02:00 PM CET, at the Company’s registered office: Boulevard Patience & Beaujonc 3/1, 4000 Liège, Belgium.

All AGM-related documents being the formal Convening Notice, agenda, proposed resolutions, and all participation and voting formalities are available on the Hyloris website <https://hyloris.com/2026-shareholders-meeting/> and on the ABN Amro Platform www.abnamro.com/evoting.

Only persons whose ownership of shares is registered on **26 May 2026 at midnight (24:00) Belgian time** (the “Registration Date”) are entitled to participate and vote. Those registered via the ABN Amro Platform will receive a follow-up email on the Registration Date. Shareholders who have notified their intention to participate to the Annual General Shareholders Meeting in Liège by no later than **3 June 2026**, can attend in person.

About Hyloris Pharmaceuticals

Hyloris is a specialty pharma group focused on reinventing and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals, and payers. The Company’s development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)(2) pathway in the U.S., or equivalent regulatory frameworks in other regions, which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio of 28 products, including 25 value-added medicines of which two are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high-barrier generic products approved in the U.S. and one additional high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. ***Where others stop, Hyloris starts and adds value through Reinventing Existing Medicines for unmet patient needs worldwide.*** Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).

For more information, visit www.hyloris.com and follow-us on [LinkedIn](#).

Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO
legal representative of Impact WITH Empathy BV
Ann.dejaeger@hyloris.com
32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO
legal representative of SVR Management BV
stijn.vanrompay@hyloris.com
32 (0)4 346 02 07

Christophe Maréchal, CFO

legal representative of CMM&C srl

Christophe.Marechal@hyloris.com

32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.